# Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

> **NCT00023998** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 80 (actual)

## Conditions studied

- Metastatic Osteosarcoma

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **DRUG:** cisplatin
- **DRUG:** methotrexate
- **DRUG:** leucovorin calcium
- **BIOLOGICAL:** filgrastim
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **BIOLOGICAL:** trastuzumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00023998
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2005-11
- **Final completion:** 2007-05
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023998, "Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00023998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*